Haemonetics Corporation
HAE
Classement en actions
#3283
Haemonetics Corporation is a healthcare enterprise dedicated to providing... Haemonetics Corporation is a healthcare enterprise dedicated to providing medical products and comprehensive solutions, structured into three main business areas: Plasma, Blood Center, and Hospital. In its Plasma segment, the company develops automated plasma collection systems, exemplified by the NexSys PCS and PCS2 devices, along with necessary disposables and intravenous solutions. It also offers integrated information technology platforms and the NexLynk DMS donor management system to help plasma customers efficiently manage their donors, operations, and supply chains. The Blood Center division provides advanced automated blood component and manual whole blood collection technologies. This includes MCS brand apheresis equipment for selectively collecting blood components, as well as disposable kits for whole blood collection and storage. Its software offerings feature the SafeTrace Tx blood bank information system and BloodTrack, a sophisticated suite of blood management software and hardware designed to enhance hospital blood bank functionalities and facilitate bedside transfusions. For the Hospital sector, Haemonetics offers hemostasis analyzer systems like TEG, ClotPro, and HAS, which deliver crucial assessments of a patient's overall clotting ability. The TEG Manager software links these analyzers throughout a facility, enabling clinicians to remotely access active and past test results to inform treatment decisions. Additionally, the Cell Saver Elite+ system supports autologous blood recovery across a wide range of surgical procedures, including cardiovascular, orthopedic, trauma, transplant, vascular, obstetrical, and gynecological operations. The company distributes its products and solutions through its own direct sales teams, independent distributors, and sales representatives. Haemonetics Corporation was established in 1971 and is based in Boston, Massachusetts.
Prix de l'action
$118.26
Dernière synchronisation: 2026-10-20
Capitalisation boursière
$5.38B
Changement (1 jour)
-0.20%
Changement (1 an)
131.02%
Pays
US
Échange Haemonetics Corporation (HAE)
Catégorie
Healthcare
Ratio P/E pour Haemonetics Corporation (HAE)
Ratio P/E au October 2026 TTM : 58.79
Selon les derniers rapports financiers et le cours de l'action de Haemonetics Corporation, le ratio P/E actuel (TTM) est de 58.79. À la fin de l’année 2024, le P/E de l’entreprise était de 36.57.
Historique du ratio P/E pour Haemonetics Corporation de 2000 à 2026
Ratio P/E à la fin de chaque année
| Année | Ratio P/E | Changez |
|---|---|---|
| 2026 (TTM) | 58.79 | 209.92% |
| 2025 | 18.97 | -48.14% |
| 2024 | 36.57 | 0.43% |
| 2023 | 36.41 | -51.54% |
| 2022 | 75.14 | 5.15% |
| 2021 | 71.46 | 6.87% |
| 2020 | 66.87 | -18.39% |
| 2019 | 81.94 | -3.25% |
| 2018 | 84.69 | -206.46% |
| 2017 | -79.55 | 146.27% |
| 2016 | -32.30 | -123.96% |
| 2015 | 134.83 | 185.97% |
| 2014 | 47.15 | -14.48% |
| 2013 | 55.13 | 108.66% |
| 2012 | 26.42 | 26.60% |
| 2011 | 20.87 | -15.24% |
| 2010 | 24.62 | 5.04% |
| 2009 | 23.44 | -19.61% |
| 2008 | 29.16 | 14.54% |
| 2007 | 25.46 | 30.83% |
| 2006 | 19.46 | -27.03% |
| 2005 | 26.67 | 2.01% |
| 2004 | 26.14 | 34.39% |
| 2003 | 19.45 | -29.80% |
| 2002 | 27.71 | -76.06% |
| 2001 | 115.73 | 274.57% |
| 2000 | 30.90 | 0.00% |
Ratio P/E pour des entreprises similaires ou concurrentes
| Entreprise | P/E Ratio | Différence du P/E Ratio | Pays |
|---|---|---|---|
| 33.11 | -43.68% |
US
|
|
| 21.39 | -63.62% |
IE
|
|
| 28.94 | -50.77% |
US
|
|
| 17.34 | -70.51% |
US
|
|
| - | - |
DE
|
Comment lire un P/E ratio ?
Le ratio Prix/Bénéfice (P/E Ratio) mesure la relation entre le cours de l'action d'une entreprise et ses bénéfices par action.
Un P/E bas mais positif indique une entreprise qui génère des bénéfices élevés par rapport à sa valorisation et qui pourrait être sous-évaluée. Un P/E négatif élevé (proche de 0) indique des pertes importantes.
Les entreprises avec un P/E supérieur à 30 ou négatif sont généralement considérées comme des "actions de croissance", ce qui signifie que les investisseurs s'attendent à ce qu'elles se développent ou deviennent rentables.
Les entreprises avec un P/E positif inférieur à 10 sont généralement considérées comme des "actions de valeur", car elles sont déjà très rentables mais avec peu de potentiel de croissance.